Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

**media[646566]**

Ocugen Secures Licensing Agreement for OCU400 in Korea

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed a binding term sheet with a prominent pharmaceutical and healthcare company in Korea, granting exclusive Korean rights to OCU400, its experimental gene therapy for retinitis pigmentosa (RP). Under the prospective licensing agreement, Ocugen will receive up to $11 million in upfront payments and near-term development milestones. The deal also includes sales milestones of $1 million for every $1…

Release - Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Channelchek

June 5, 2025 PDF Version Upfront fees and near-term development milestone payments totaling up to $11 million Sales milestones of $150 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, to…

Ocugen signs term sheet for korean licensing of OCU400 gene therapy

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).